• Gerald L Andriole, E David Crawford, Robert L Grubb, Saundra S Buys, David Chia, Timothy R Church, Mona N Fouad, Edward P Gelmann, Paul A Kvale, Douglas J Reding, Joel L Weissfeld, Lance A Yokochi, Barbara O'Brien, Jonathan D Clapp, Joshua M Rathmell, Thomas L Riley, Richard B Hayes, Barnett S Kramer, Grant Izmirlian, Anthony B Miller, Paul F Pinsky, Philip C Prorok, John K Gohagan, Christine D Berg, and PLCO Project Team.
• Washington University School of Medicine, St. Louis, USA.
• N. Engl. J. Med. 2009 Mar 26; 360 (13): 131013191310-9.

BackgroundThe effect of screening with prostate-specific-antigen (PSA) testing and digital rectal examination on the rate of death from prostate cancer is unknown. This is the first report from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial on prostate-cancer mortality.MethodsFrom 1993 through 2001, we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects). Men in the screening group were offered annual PSA testing for 6 years and digital rectal examination for 4 years. The subjects and health care providers received the results and decided on the type of follow-up evaluation. Usual care sometimes included screening, as some organizations have recommended. The numbers of all cancers and deaths and causes of death were ascertained.ResultsIn the screening group, rates of compliance were 85% for PSA testing and 86% for digital rectal examination. Rates of screening in the control group increased from 40% in the first year to 52% in the sixth year for PSA testing and ranged from 41 to 46% for digital rectal examination. After 7 years of follow-up, the incidence of prostate cancer per 10,000 person-years was 116 (2820 cancers) in the screening group and 95 (2322 cancers) in the control group (rate ratio, 1.22; 95% confidence interval [CI], 1.16 to 1.29). The incidence of death per 10,000 person-years was 2.0 (50 deaths) in the screening group and 1.7 (44 deaths) in the control group (rate ratio, 1.13; 95% CI, 0.75 to 1.70). The data at 10 years were 67% complete and consistent with these overall findings.ConclusionsAfter 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups. (ClinicalTrials.gov number, NCT00002540.)2009 Massachusetts Medical Society

19 keywords...

hide…